Arvinas (ARVN) to Post Quarterly Earnings on Tuesday

Arvinas (NASDAQ:ARVN) is anticipated to post its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Arvinas to announce earnings of ($0.24) per share and revenue of $60.7080 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.05. The firm had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $16.61 million. Arvinas had a negative return on equity of 44.38% and a negative net margin of 247.54%.The firm’s quarterly revenue was down 91.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.14 earnings per share. On average, analysts expect Arvinas to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Performance

Shares of Arvinas stock opened at $8.03 on Monday. The stock has a 50 day moving average of $8.09 and a 200 day moving average of $10.35. The firm has a market capitalization of $518.10 million, a price-to-earnings ratio of -2.42 and a beta of 1.74. Arvinas has a fifty-two week low of $6.05 and a fifty-two week high of $14.51.

Insiders Place Their Bets

In related news, CEO Randy Teel sold 9,657 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $95,990.58. Following the sale, the chief executive officer owned 287,218 shares in the company, valued at approximately $2,854,946.92. The trade was a 3.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $9.94, for a total value of $110,413.52. Following the transaction, the insider directly owned 191,395 shares in the company, valued at approximately $1,902,466.30. The trade was a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 41,728 shares of company stock worth $402,649 over the last ninety days. Corporate insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On Arvinas

Several institutional investors have recently bought and sold shares of ARVN. Tower Research Capital LLC TRC lifted its position in shares of Arvinas by 491.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company’s stock worth $43,000 after purchasing an additional 4,835 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company’s stock valued at $49,000 after purchasing an additional 3,500 shares in the last quarter. Abel Hall LLC purchased a new stake in Arvinas during the 4th quarter worth approximately $125,000. Corient Private Wealth LLC purchased a new stake in Arvinas during the 4th quarter worth approximately $127,000. Finally, Jain Global LLC purchased a new stake in Arvinas during the 3rd quarter worth approximately $95,000. 95.19% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen raised Arvinas from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 26th. BTIG Research raised their price objective on Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Weiss Ratings lowered shares of Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. Zacks Research raised shares of Arvinas from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 26th. Finally, Barclays upped their target price on shares of Arvinas from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $15.42.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.